Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

Steven M. Jones, Heinz Feldmann, Ute Ströher, Joan B. Geisbert, Lisa Fernando, Allen Grolla, Hans Dieter Klenk, Nancy J. Sullivan, Viktor E. Volchkov, Elizabeth A. Fritz, Kathleen M. Daddario, Lisa E. Hensley, Peter B. Jahrling, Thomas Geisbert

Research output: Contribution to journalArticle

431 Citations (Scopus)

Abstract

Vaccines and therapies are urgently needed to address public health needs stemming from emerging pathogens and biological threat agents such as the filoviruses Ebola virus (EBOV) and Marburg virus (MARV). Here, we developed replication-competent vaccines against EBOV and MARV based on attenuated recombinant vesicular stomatitis virus vectors expressing either the EBOV glycoprotein or MARV glycoprotein. A single intramuscular injection of the EBOV or MARV vaccine elicited completely protective immune responses in nonhuman primates against lethal EBOV or MARV challenges. Notably, vaccine vector shedding was not detectable in the monkeys and none of the animals developed fever or other symptoms of illness associated with vaccination. The EBOV vaccine induced humoral and apparent cellular immune responses in all vaccinated monkeys, whereas the MARV vaccine induced a stronger humoral than cellular immune response. No evidence of EBOV or MARV replication was detected in any of the protected animals after challenge. Our data suggest that these vaccine candidates are safe and highly efficacious in a relevant animal model.

Original languageEnglish (US)
Pages (from-to)786-790
Number of pages5
JournalNature Medicine
Volume11
Issue number7
DOIs
StatePublished - Jul 2005
Externally publishedYes

Fingerprint

Marburgvirus
Ebolavirus
Attenuated Vaccines
Synthetic Vaccines
Viruses
Primates
Ebola Vaccines
Vaccines
Cellular Immunity
Haplorhini
Glycoproteins
Active Immunotherapy
Vesicular Stomatitis
Animals
Intramuscular Injections
Biological Factors
Humoral Immunity
Virus Replication
Vaccination
Fever

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Jones, S. M., Feldmann, H., Ströher, U., Geisbert, J. B., Fernando, L., Grolla, A., ... Geisbert, T. (2005). Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nature Medicine, 11(7), 786-790. https://doi.org/10.1038/nm1258

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. / Jones, Steven M.; Feldmann, Heinz; Ströher, Ute; Geisbert, Joan B.; Fernando, Lisa; Grolla, Allen; Klenk, Hans Dieter; Sullivan, Nancy J.; Volchkov, Viktor E.; Fritz, Elizabeth A.; Daddario, Kathleen M.; Hensley, Lisa E.; Jahrling, Peter B.; Geisbert, Thomas.

In: Nature Medicine, Vol. 11, No. 7, 07.2005, p. 786-790.

Research output: Contribution to journalArticle

Jones, SM, Feldmann, H, Ströher, U, Geisbert, JB, Fernando, L, Grolla, A, Klenk, HD, Sullivan, NJ, Volchkov, VE, Fritz, EA, Daddario, KM, Hensley, LE, Jahrling, PB & Geisbert, T 2005, 'Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses', Nature Medicine, vol. 11, no. 7, pp. 786-790. https://doi.org/10.1038/nm1258
Jones SM, Feldmann H, Ströher U, Geisbert JB, Fernando L, Grolla A et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nature Medicine. 2005 Jul;11(7):786-790. https://doi.org/10.1038/nm1258
Jones, Steven M. ; Feldmann, Heinz ; Ströher, Ute ; Geisbert, Joan B. ; Fernando, Lisa ; Grolla, Allen ; Klenk, Hans Dieter ; Sullivan, Nancy J. ; Volchkov, Viktor E. ; Fritz, Elizabeth A. ; Daddario, Kathleen M. ; Hensley, Lisa E. ; Jahrling, Peter B. ; Geisbert, Thomas. / Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. In: Nature Medicine. 2005 ; Vol. 11, No. 7. pp. 786-790.
@article{e0aecff0bc504cc9b590715e4cd53c27,
title = "Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses",
abstract = "Vaccines and therapies are urgently needed to address public health needs stemming from emerging pathogens and biological threat agents such as the filoviruses Ebola virus (EBOV) and Marburg virus (MARV). Here, we developed replication-competent vaccines against EBOV and MARV based on attenuated recombinant vesicular stomatitis virus vectors expressing either the EBOV glycoprotein or MARV glycoprotein. A single intramuscular injection of the EBOV or MARV vaccine elicited completely protective immune responses in nonhuman primates against lethal EBOV or MARV challenges. Notably, vaccine vector shedding was not detectable in the monkeys and none of the animals developed fever or other symptoms of illness associated with vaccination. The EBOV vaccine induced humoral and apparent cellular immune responses in all vaccinated monkeys, whereas the MARV vaccine induced a stronger humoral than cellular immune response. No evidence of EBOV or MARV replication was detected in any of the protected animals after challenge. Our data suggest that these vaccine candidates are safe and highly efficacious in a relevant animal model.",
author = "Jones, {Steven M.} and Heinz Feldmann and Ute Str{\"o}her and Geisbert, {Joan B.} and Lisa Fernando and Allen Grolla and Klenk, {Hans Dieter} and Sullivan, {Nancy J.} and Volchkov, {Viktor E.} and Fritz, {Elizabeth A.} and Daddario, {Kathleen M.} and Hensley, {Lisa E.} and Jahrling, {Peter B.} and Thomas Geisbert",
year = "2005",
month = "7",
doi = "10.1038/nm1258",
language = "English (US)",
volume = "11",
pages = "786--790",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

AU - Jones, Steven M.

AU - Feldmann, Heinz

AU - Ströher, Ute

AU - Geisbert, Joan B.

AU - Fernando, Lisa

AU - Grolla, Allen

AU - Klenk, Hans Dieter

AU - Sullivan, Nancy J.

AU - Volchkov, Viktor E.

AU - Fritz, Elizabeth A.

AU - Daddario, Kathleen M.

AU - Hensley, Lisa E.

AU - Jahrling, Peter B.

AU - Geisbert, Thomas

PY - 2005/7

Y1 - 2005/7

N2 - Vaccines and therapies are urgently needed to address public health needs stemming from emerging pathogens and biological threat agents such as the filoviruses Ebola virus (EBOV) and Marburg virus (MARV). Here, we developed replication-competent vaccines against EBOV and MARV based on attenuated recombinant vesicular stomatitis virus vectors expressing either the EBOV glycoprotein or MARV glycoprotein. A single intramuscular injection of the EBOV or MARV vaccine elicited completely protective immune responses in nonhuman primates against lethal EBOV or MARV challenges. Notably, vaccine vector shedding was not detectable in the monkeys and none of the animals developed fever or other symptoms of illness associated with vaccination. The EBOV vaccine induced humoral and apparent cellular immune responses in all vaccinated monkeys, whereas the MARV vaccine induced a stronger humoral than cellular immune response. No evidence of EBOV or MARV replication was detected in any of the protected animals after challenge. Our data suggest that these vaccine candidates are safe and highly efficacious in a relevant animal model.

AB - Vaccines and therapies are urgently needed to address public health needs stemming from emerging pathogens and biological threat agents such as the filoviruses Ebola virus (EBOV) and Marburg virus (MARV). Here, we developed replication-competent vaccines against EBOV and MARV based on attenuated recombinant vesicular stomatitis virus vectors expressing either the EBOV glycoprotein or MARV glycoprotein. A single intramuscular injection of the EBOV or MARV vaccine elicited completely protective immune responses in nonhuman primates against lethal EBOV or MARV challenges. Notably, vaccine vector shedding was not detectable in the monkeys and none of the animals developed fever or other symptoms of illness associated with vaccination. The EBOV vaccine induced humoral and apparent cellular immune responses in all vaccinated monkeys, whereas the MARV vaccine induced a stronger humoral than cellular immune response. No evidence of EBOV or MARV replication was detected in any of the protected animals after challenge. Our data suggest that these vaccine candidates are safe and highly efficacious in a relevant animal model.

UR - http://www.scopus.com/inward/record.url?scp=22544441308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22544441308&partnerID=8YFLogxK

U2 - 10.1038/nm1258

DO - 10.1038/nm1258

M3 - Article

C2 - 15937495

AN - SCOPUS:22544441308

VL - 11

SP - 786

EP - 790

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 7

ER -